ArticleBMC endocrine disorders2026
Incidence and risk factors for osteoporosis in people with type 2 diabetes mellitus in Thailand.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is documented to alter bone structure and increase fracture risk. This study aimed to determine the risk factors and incidence rate of osteoporosis in Thai adults with T2DM.
methodsA retrospective cohort study was conducted at Ramathibodi Hospital. People aged 18 or above who were diagnosed with T2DM between January 2010 and December 2019 and started diabetic medication were included. Participants with a history of osteoporosis were excluded. Osteoporosis was diagnosed by BMD T-score ≤ −2.5, ICD-10 for osteoporosis, ICD-9 for fragility fracture, or prescription of osteoporosis medication. The participants who did not meet the criteria were categorized as non-osteoporosis. Univariate and multivariate Cox regression analyses were used to determine risk factors for osteoporosis.
resultsA total of 25,635 participants were recruited. During the study period, 790 participants were diagnosed with osteoporosis. The incidence rate was 58/10,000 person-year. Older age and female sex were associated with a greater risk of osteoporosis, with hazard ratios (HR) of 1.07 (1.06–1.08) and 4.41 (3.57–5.44), respectively. In contrast, higher BMI was associated with a reduction in osteoporosis [HR 0.95 (0.93–0.96)]. For Diabetes-related risk factors, dipeptidyl peptidase-4 inhibitors (DPP4-inhibitors), insulin, and thiazolidinediones were associated with a higher risk of osteoporosis; HR were 1.36 (1.05–1.75), 1.32 (1.05–1.65), and 1.39 (1.01–1.92), respectively. Dyslipidemia was also associated with osteoporosis [HR 1.36 (1.12–1.65)].
conclusionOlder women with T2DM and dyslipidemia had a significantly higher risk of osteoporosis. Furthermore, insulin, thiazolidinediones, and DPP4 inhibitors are associated with increased fracture risk when compared to metformin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.